Cyclooxygeanse-2 promotes metastasis in osteosarcoma
Authors:
Open Access
- 4 July 2015
- journal article
- review article
- Published by Springer Nature in Cancer Cell International
- Vol. 15 (1) , 69
Abstract
Cyclooxygenase-2 (COX-2), an inducible form of the enzyme that catalyzes the first step in the synthesis of prostanoids, is associated with carcinogenesis, which is suspected to promote angiogenesis and tissue invasion of tumors and resistance to apoptosis. COX-2 is also involved in metastasis and poor prognosis of cancer. Osteosarcoma with COX-2 positivity is from 67 to 92 %. COX-2-positive rate in metastatic lesions was greater than that of biopsy and/or resected samples of the primary site in osteosarcoma. And, what role does COX-2 play in osteosarcoma metastasis? Genetic studies support a cause-effect connection between COX-2 and tumorigenesis. COX-2 expression had a poor prognosis with regard to metastasis, and patients with increased COX-2 expression in lung metastases died of the disease. COX-2 expression has also been established as a marker in human osteosarcoma, and COX-2 inhibition has been suggested as a possible way of improving therapeutic outcome. In addition, COX-inhibitors inhibit the tumor initiation, matrix metalloproteinases (MMPs), cell differentiation and T cell proliferation and suppression of the antitumor activity of natural killer cells and macrophages, angiogenic mechanism. Therefore, we can exert the COX-inhibitors to potentialize the effects of chemotherapeutic agents, and reverse the metastasis in osteosarcoma to facilitate the patient who may benefit from addition of COX-inhibitors to standard cytotoxic therapy.Keywords
This publication has 45 references indexed in Scilit:
- Correction: Identification of CBX3 and ABCA5 as Putative Biomarkers for Tumor Stem Cells in OsteosarcomaPLOS ONE, 2012
- Identification of CBX3 and ABCA5 as Putative Biomarkers for Tumor Stem Cells in OsteosarcomaPLOS ONE, 2012
- Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literatureClinical & Experimental Metastasis, 2011
- RNAi-mediated knockdown of cyclooxygenase2 inhibits the growth, invasion and migration of SaOS2 human osteosarcoma cells: a case control studyJournal of Experimental & Clinical Cancer Research, 2011
- Cyclooxygenase-2 Overexpression Predicts Poor Survival in Patients with High-grade Extremity Osteosarcoma: A Pilot StudyClinical Orthopaedics and Related Research, 2009
- Expression of an Exogenous Human Oct-4 Promoter Identifies Tumor-Initiating Cells in OsteosarcomaCancer Research, 2009
- COX-2 Expression Correlates With Survival in Patients With Osteosarcoma Lung MetastasesJournal of Pediatric Hematology/Oncology, 2008
- Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cellsExperimental & Molecular Medicine, 2007
- Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routesCarcinogenesis, 2005
- The Hallmarks of CancerCell, 2000